Efficacy of triple therapy with thymalfasin, peginterferon α-2a, and ribavirin for the treatment of hispanic chronic HCV nonresponders
Journal Title: Annals of Hepatology - Year 2008, Vol 7, Issue 4
Abstract
Background/Aims: Thymalfasin has shown efficacy in the treatment of chronic HCV infection. The aim of this study was to evaluate the efficacy and tolerability of triple therapy with thymalfasin, peginterferon α-2a (PEG-IFN α-2a), and ribavirin in Hispanic patients with chronic viral hepatitis C who were nonresponders to prior treatment with interferon alfa (IFN-α)/ribavirin. Methods: In this open-label study, 40 subjects received thymalfasin (1.6 mg twice a week), PEG-IFN α-2a (180 µg once a week), and ribavirin (800-1,000 mg/day) for 48 weeks. All patients had positive HCV RNA by PCR analysis, abnormal levels of ALT, compensated hepatic disease, and liver biopsy with chronic damage. Results: Viral response was observed in 52.5% patients at week 12 and 50% at week 24. Of the per protocol group, 52.6% showed an end-of-treatment response at week 48 and 21.1% achieved an SVR at week 72. Among genotype 1 patients, 23.5% achieved an SVR at week 72. A reduction of the dose of PEG IFN α-2a and ribavirin was required. Thymalfasin was well tolerated without dose reduction. Conclusion: Triple therapy with thymalfasin, PEG IFN α-2a, and ribavirin is an effective treatment option for difficult-to-treat HCV patients who are refractory to prior conventional treatment, with adequate tolerability.
Authors and Affiliations
Jorge Poo, Francisco Sánchez Ávila, David Kershenobich, Xochitl García Samper, Rocio Torres-Ibarra, J Gongora, Carlos Cano, Miguel Parada, Misael Uribe
Keywords
Related Articles
- EP ID EP77812
- DOI -
- Views 148
- Downloads 0
Evaluation the value of markers for prediction of portal vein thrombosis after devascularization
Aim. To evaluate the value of D-dimer and P-selectin in cirrhotic portal hypertension (PHT) patients for prediction of portal vein thrombosis (PVT) after devascularization. Material and methods. 137 patients withcirrhoti...
Optimizing dosage and duration therapy for chronic hepatitis C «difficult-to-treat patients»
Chilaiditi syndrome. An uncommon cause of crampy, upper abdominal pain
Hospital performance reports based on severity adjusted mortality rates in patients with cirrhosis depend on the method of risk adjustment
Background. Hospital outcome report cards are used to judge provider performance, including for liver transplantation. We aimed to determine the impact of the choice of risk adjustment method on hospital rankings based...
Elevated acetaminophen level: Could it be a red herring?